Search results
Results from the WOW.Com Content Network
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Change is in the air. A new President-elect and the possibility of an end to the pandemic. Some things, however, will always stay the same.Like small cap biotech stocks skyrocketing following the ...
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to ...
For premium support please call: 800-290-4726 more ways to reach us
An intraday percentage gain is defined as the difference between the previous trading session's closing price and the intraday high of the following trading session. The closing percentage change denotes the ultimate percentage change recorded after the corresponding trading session's close.
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 20.80% and 29.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...